The abstract is read at the publisher; the summary is JClub's.
Cognitive impairment and dementia are increasingly linked to type 2 diabetes, but it remains unclear whether cognitive decline in T2D is modifiable, despite recognized mechanisms.
- Why it matters: The field needs to know whether cognitive decline in T2D can be changed, not just explained by metabolic dysregulation, vascular injury, neuroinflammation, and defective brain insulin signaling.
- What they did: This review surveys emerging neuroprotective strategies, emphasizing pharmacological and lifestyle interventions, and highlights evidence that metformin, sodium-glucose cotransporter 2 inhibitors, and glucagon-like peptide-1 receptor agonists may affect brain metabolism, inflammation, and vascular integrity beyond glucose lowering.
- The result: The authors propose making cognitive preservation an explicit therapeutic goal by integrating metabolic control with targeted brain-protective approaches, suggesting a modifiable management direction.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.